Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen

First in-human, Phase 1/2a data from APPROACH preventive HIV-1 vaccine clinical trial to be featured in oral presentation and included in official IAS press program. Interim results from the Phase 3 pivotal EMERALD trial investigating darunavir-based single-tablet regimen selected for oral presentation; data submitted to regulatory authorities for EMA approval, September 2017.
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

If you’re staying shut in your home, anxious about when you will finally be able to take a stroll outside or whether you or someone close to you will be infected by the novel coronavirus, you are not the only one. In the U.S. alone, half of the adults report high levels of anxiety due to the COVID-19, according to the  American Psychiatric Association. The ongoing pandemic is exerting the whole world both physically and mentally. One thing is sure to be asked by everyone: when will all this be over? Some think that things will never get back to normal. Acclaimed sci-fi writer Ted Chiang says that “we do...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine digital technology digital health tech digital health technologies coronavirus covid covid19 Source Type: blogs
This report highlights some of the knowledge shared at the SPSASV.
Source: Journal of Venomous Animals and Toxins including Tropical Diseases - Category: Tropical Medicine Source Type: research
No abstract available
Source: Epidemiology - Category: Epidemiology Tags: Letters Source Type: research
Conclusions: We found age-specific prevalence of HPV infection showed a “U-shaped” pattern for high and low risk HPV, suggesting the importance of screening among younger women and the necessary of detection among older women. We found a novel co-infection preference of HPV 16/18 with 31, 52, and 58, suggesting a need of developing and marketing prophylactic HPV vaccines that protect against more genotypes in China.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Computational vaccinology includes epitope mapping, antigen selection, and immunogen design using computational tools. Tools that facilitate the in silico prediction of immune response to biothreats, emerging infectious diseases, and cancers can accelerate the design of novel and next generation vaccines and their delivery to the clinic. Over the past 20 years, vaccinologists, bioinformatics experts, and advanced programmers based in Providence, Rhode Island, USA have advanced the development of an integrated toolkit for vaccine design called iVAX, that is secure and user-accessible by internet. This integrated set of immu...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
HIV-1 positive elite controllers or suppressors control viral replication without antiretroviral therapy, likely via CTL-mediated elimination of infected cells, and therefore represent a model of an HIV-1 functional cure. Efforts to cure HIV-1 accordingly rely on the existence or generation of antigen-specific cytotoxic T lymphocytes (CTL) to eradicate infected cells upon reversal of latency. Detecting and quantifying these HIV-1-specific CTL responses will be crucial for developing vaccine and T cell-based immunotherapies. A recently developed assay, called MANAFEST, uses T cell receptor (TCR) Vβ sequencing of peptid...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Today, Cochrane announces the launch of itsCOVID-19 Study Register– a one-stop shop for primary research studies on COVID-19. The aim of the register is to support rapid evidence synthesis by all systematic review producers, includingCochrane's work on Rapid Reviews in response to COVID-19. The register helps systematic reviewers prioritize topics, identify available evidence, and produce urgently needed reviews for front-line health professionals, public health policymakers, and research teams developing new therapeutic, diagnostic, and preventive interventions for COVID-19.  The newCOVID-19 Study Register...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
MONDAY, April 6, 2020 -- Public health officials have been warning that a COVID-19 vaccine will not be available to the public for 12 to 18 months, dampening hopes that there will be a quick end to the global pandemic nightmare. But Chinese...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Purpose of review The available vaccine and therapies against hepatitis B virus (HBV) rarely eliminate chronic infection with the virus. High mortality resulting from complicating cirrhosis and hepatocellular carcinoma makes improving anti-HBV therapy an important priority. Recent advances with using gene therapy to counter HBV have potential and are the focus of this review. Recent findings The stable replication-competent HBV intermediate comprising covalently closed circular DNA (cccDNA) is the template for expression of all viral genes. Inactivating cccDNA has thus been a focus of research aimed at achieving cure ...
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: HIV AND HEPATITIS B CURE: Edited by Sharon R. Lewin and Peter A. Revill Source Type: research
One would hope that it does not require an ongoing pandemic and related hysteria to point out that old people have poorly functioning immune systems, and thus suffer disproportionately the burden of infectious disease. But perhaps it does. The 2017-2018 seasonal influenza, a modestly more severe occurrence of something that happens every year, killed something like 60,000 people in the US alone, with little notice or comment. There is nothing so terrible that it won't be accepted - ignored, even - if it is normal. Floodgates of funding for infectious disease research and development have been opened in response to C...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
More News: Clinical Trials | Pharmaceuticals | Prezista | Vaccines